Biologics License Application (BLA) submission supported by Phase III RATIONALE 302 trial, which met primary endpoint of improvement in overall survival (OS) in people with advanced or metastatic esophageal squamous cell carcinoma (ESCC) who had received prior systemic therapy1
ESCC is most common type of esophageal cancer globally and sixth leading cause of cancer-related death worldwide, with five-year survival rate at 19.9%2,3
http://www.pharmastrategies.org/wp-content/uploads/2019/12/Pharma-Strategies-Website-Logo-300x138.png00English RSS Feedhttp://www.pharmastrategies.org/wp-content/uploads/2019/12/Pharma-Strategies-Website-Logo-300x138.pngEnglish RSS Feed2021-09-13 05:00:002021-09-13 05:00:00Novartis announces first FDA filing acceptance for anti-PD-1 antibody tislelizumab for people with esophageal cancer
